Xencor Licenses Out IP To Help Fund Internal Pipeline
This article was originally published in The Pink Sheet Daily
The California biotech has licensed intellectual property to Merck to help finance its own development efforts around immune-modulating drugs.
You may also be interested in...
Oncology-focused pharmas and multiple myeloma players, as well as would-be MM competitors, top Wall Street’s list of possible Onyx buyers. A successful deal could aid the longstanding biotech rally that has retrenched in recent weeks.
After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.